Loading...
Loading...
ALLO| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 54.7M |
| Gross Profit | -54.6M |
| Operating Expense | 71.9M |
| Operating I/L | -71.9M |
| Other Income/Expense | -13.9M |
| Interest Income | 6.3M |
| Pretax | -85.8M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | -85.8M |
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company specializing in the development and commercialization of genetically engineered allogeneic T cell therapies for cancer treatment. Its product pipeline includes UCART19 for pediatric and adult patients with R/R CD19 positive B-cell ALL, ALLO-501 and ALLO-501A for R/R non-Hodgkin lymphoma and large B-cell lymphoma, ALLO-715 for R/R multiple myeloma, and other candidates targeting renal cell cancer, acute myeloid leukemia, and neuroendocrine tumors. The company generates revenue through the development, manufacturing, and commercialization of these allogeneic CAR T cell product candidates.
